C
rohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with a broad spectrum of clinical presentations. Nearly 50% of patients with CD develop complications such as stricturing or penetrating disease, whereas over 40% require surgery in their lifetime. 1, 2 Because of this significant heterogeneity in disease course, identification of genetic and environmental factors that allow for better patient stratification may afford opportunities for personalized medicine. Although recent studies have identified a number of novel genetic and environmental factors that are associated with the risk of disease onset, little is known about the role of environmental and genetic factors in disease progression. [3] [4] [5] [6] Obesity, as defined by body mass index (BMI), has been linked to the increased risk of CD, likely through its association Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (http://www.ibdjournal.org).
with intestinal inflammation, permeability, and changes in gut microbiota. [7] [8] [9] [10] [11] However, we previously found that BMI was not associated with the increased risk of CD complications. 12 In addition, we did not observe an interaction between BMI and genetic predisposition and risk of CD complications. Nonetheless, as evidenced by the presence of creeping fat and mesenteric fat hypertrophy among patients with CD, it is possible that visceral adipose tissue (VAT), which also contains the more biologically active adipocytes, and not total obesity, is linked to CD progression. 13 VAT has been shown to play an active role in systemic inflammation through production of proinflammatory mediators such as tumor necrosis factor-a (TNF-a), and anti-inflammatory cytokines such as interleukin-10. 14, 15 In addition, compared with subcutaneous fat, there is a higher expression of leptin mRNA in VAT which in turn can induce TNF-a and lead to increased intestinal inflammation. 16 Compared with subcutaneous adipose tissue, VAT secretes 3-fold more interleukin-6. 17 A number of previous studies have evaluated the impact of VAT on disease incidence and progression; however, these studies have been limited by their sample size and lack of detailed information on important confounders such as smoking. 16, [18] [19] [20] [21] In addition, previous studies have not accounted for the potential influence of genetic variants on the association between VAT and CD progression. The importance of genetics in disease progression has been highlighted by twin studies demonstrating similar disease phenotypes across identical twins as well as a recent study demonstrating the association between genetic variants and disease phenotypes in CD. 22, 23 Therefore, a more comprehensive examination of the influence of environment on CD progression may be best characterized in the context of genetic predisposition. We therefore sought to examine the effect of visceral adiposity as measured by VAT volume and its interaction with genetic predisposition on the risk of CD complications using a large cohort of patients with CD with comprehensive information on lifestyle and genetic factors.
METHODS

Study Population
Starting in 2004, adult patients, age $18 years, with a diagnosis of CD, ulcerative colitis, or indeterminate colitis were recruited in the Prospective Registry in Inflammatory Bowel Disease Study at Massachusetts General Hospital (PRISM). At the time of recruitment, patients were interviewed by a study coordinator to collect detailed information on their disease characteristics according to the Montreal classification, lifestyle factors including smoking, BMI, and other comorbid conditions. In addition, approximately 10 mL of blood was drawn from each participant at the time of enrollment for extraction of the buffy coat. For this study, among 787 patients with CD with available genetic data in our cohort, 482 patients had at least 1 available abdominal computed tomography (CT) and therefore were eligible for inclusion. There were no significant differences in age at diagnosis, sex, race, BMI, history of smoking, and disease duration comparing individuals with at least 1 CT to those without (see Table 1 , Supplemental Digital Content 1, http://links.lww. com/IBD/B399). The Institutional Review Board at the Massachusetts General Hospital (MGH) approved this study.
VAT Measurements
Although both MRI and CT have been used for VAT measurements, because of the wide use of CT at our institution during the study period, VAT measurements were only performed using CT. 24 Suitable scans were assessed with Aquarius 3D iNtuition viewer (TeraRecon Inc., version 4.4.12, San Mateo, CA). This software traces the abdominal muscular layer and separates subcutaneous from VAT (including mesenteric adipose tissue), after which their volumes are measured within predetermined reference points, applied by the researcher, using the Fat Analysis 3D option. Using previously reported methods, adipose tissue volumes were measured from the 11th thoracic vertebra to the fifth sacral vertebra. 18, 25 As some individuals had a CT after the date of diagnosis of CD complications, we compared VAT volumes before and after CD complications among individuals with multiple CT before and after the date of disease complications, and observed no significant differences (see Table 2 , Supplemental Digital Content 1, http://links.lww.com/IBD/B399).
Outcome Ascertainment
We defined CD complications as the presence of penetrating disease, stricturing disease, perianal disease, or the need for having a bowel resection. At the time of enrollment, information on disease behavior (penetrating, stricturing, and perianal disease) and previous surgeries was collected and confirmed by the review of medical records and further verified by primary gastroenterologists.
Assessment of Other Covariates
Participants reported their height at the time of enrollment, whereas information on weight was obtained from the review of medical records at the time of the CT. BMI was calculated from height and weight. We also collected information on sex, race, smoking status at the time of enrollment (never, past, or current), age at diagnosis, disease location (ileal, colonic, and ileocolonic), and ever use of CD-related medications (mesalamines, thiopurines, methotrexate, and anti-TNF). Data on date of diagnosis, age of diagnosis, disease location, and medications were confirmed by the review of medical records and verified by primary gastroenterologists.
Genotyping and Computation of Genetic Risk Score
We have previously reported in detail information on genotyping and computation of genetic risk score (GRS). 12 Briefly, genotyping was performed on the Illumina Immunochip at the Broad Institute (Cambridge, MA). We used the most recent meta-analysis of genome-wide association studies to identify 140 single-nucleotide polymorphisms (SNPs) associated with the risk of CD. 6 GRS was calculated on the basis of these SNPs using a previously reported weighted method. 26, 27 Each SNP was recoded as 0, 1, or 2 according to the number of CD increasing risk alleles, and each SNP was weighted by its relative effect size (regression b coefficient) derived from the previously reported meta-analysis data. We created the GRS for CD using the equa-
, where b i is the b coefficient of SNP i on susceptibility to CD. The GRS CD was previously shown to be associated with the higher risk of CD complications in PRISM. 28 We categorized individuals according to their GRS into high and low risk groups based on the median GRS value of the entire cohort.
Statistical Analysis
We compared the baseline characteristics of study participants across quartiles of VAT residuals using Chi-square tests for categorical variables and Kruskal-Wallis H test for continuous variables. Because VAT and BMI were highly correlated (Spearman correlation, r ¼ 0.69, P , 0.001), we obtained the component of VAT volume that is not explained by BMI, i.e., VAT residuals, by regressing VAT volume on BMI. These VAT residuals were used as the exposure variables in our study to (1) examine the association between VAT and CD complications independent of BMI and (2) to avoid collinearity in the multivariable (MV) association models. VAT volumes were entered into the models as quartiles where the cutoff for each quartile was determined from the distribution of VAT in patients without complications. We estimated the risk of CD complications by calculating the odds ratio and 95% CI using logistic regression modeling adjusting for potential confounders. P-trends were calculated using the median value of each quartile. All models were adjusted for sex, history of smoking, time between disease diagnosis and CT, and age at diagnosis. We evaluated effect modification by genetics using cross-classified categories of GRS and VAT volumes. We tested the significance of this interaction using the log likelihood ratio test to compare the fit of a model containing cross-classified categories with that of a model where VAT volume and GRS CD were independent variables. Same methods were used to evaluate possible interactions with individual CD SNPs. We used SPSS Statistics version 20 (IBM Corp., Armonk, NY) to perform all analyses. All P-values were 2 sided and P , 0.05 was considered significant.
RESULTS
Among 482 patients with available information on VAT volume, 174 developed penetrating disease, 132 developed stricturing disease, 147 developed perianal disease, and 252 required surgery. Compared with the participants in the lowest quartile of VAT volume, patients in the highest quartile of VAT volume were older at the time of diagnosis, had higher BMIs, and more likely to be smokers ( Table 1) .
The risk of surgery seemed to increase with increasing VAT volume (P trend ¼ 0.006). Compared with participants in the lowest quartile of VAT volume, the MV-adjusted risk of surgery among participants in the highest quartile was 2.02, 95% CI 1.09 to 3.76 (Table 2) . These results were not significantly altered in analyses where participants with penetrating disease were excluded (P trend ¼ 0.003). Similarly, the risk of penetrating disease seemed to be positively associated with VAT volume (P trend ¼ 0.02). Compared with participants in the lowest quartile of VAT volume, the MV-adjusted risk of penetrating disease was 1.95, 95% CI 1.04 to 3.67 in the highest quartile. Conversely, we did not observe an association between VAT volume and risk of perianal or stricturing disease (all P trend . 0.20). Compared with patients with CD in the lowest quartile of VAT volume, participants in the highest quartile had an MV-adjusted odds ratio of 0.68 (95% CI 0.35-1.32) for stricturing disease and 0.82 (95% CI 0.42-1.59) for penetrating disease. In exploratory analyses, we did not observe an effect modification by disease duration on the association between VAT and CD progression (All P interaction . 0.26).
Although VAT volume did not seem to differ significantly between imaging obtained before and after the occurrence of disease complications, we performed sensitivity analysis restricted to cases where a CT predated disease complications and obtained similar results. Among 223 eligible participants for these analyses, of which 70 patients required surgery, the risk of surgery seemed to increase with greater VAT volume (P trend ¼ 0.027). Compared with participants in the lowest quartile of VAT volume, the MV-adjusted risk of surgery among participants in the highest quartile was 2.43, with a 95% CI 0.95 to 6.21. Because VAT volume seemed to vary according to age of diagnosis (Table 1) , we also explored whether the association between VAT volume and risk of surgery and penetrating disease is modified by age of diagnosis and observed no interaction (P interaction ¼ 0.09 and 0.99, respectively).
We explored the possibility that the association between VAT volume and risk of CD complications may be modified by genetic predisposition, and therefore evaluated for effect modification by GRS (Fig. 1) . We failed to observe any evidence to support effect modification by GRS (as a binary variable) on the associations between VAT volume and risk of surgery, or risk of stricturing, penetrating, or perianal disease (all P interaction . 0.20). Similar results were obtained when GRS was treated as a continuous variable (all P interaction . 0.12). We also evaluated for potential interaction between CD SNPs within the risk score and VAT volume on risk of CD complications (see Table 3 , Supplemental Digital Content 2, http://links.lww.com/IBD/B400). Although there seemed to be trends toward interaction for some SNPs, none of these met the threshold for statistical significant after accounting for multiple testing (Bonferroni-corrected P ¼ 0.00036).
DISCUSSION
In a large cohort of patients with CD, we show that visceral adiposity as measured by VAT volume is associated with the increased risk of surgery and penetrating disease but not perianal or stricturing disease. In addition, genetic predisposition does not seem to modify the association between VAT volume and risk of CD complications. These findings are party supported by previous studies. Uko et al 18 evaluated the impact of VAT volume in a small cohort of pediatric IBD cases (n ¼ 114) and showed that patients with IBD have greater VAT volume values compared with healthy controls. In addition, at the time of diagnosis, greater VAT volume was associated with the increased risk of fistulizing disease. Similarly, Bunning and colleagues demonstrated a good correlation between index of VAT accumulation (VAT/total fat mass) and disease activity and complications in small cohort of adult women with CD (N ¼ 31). 19 Interestingly, a number of recent studies have also demonstrated an association between visceral adiposity and postoperative morbidity and disease recurrence in CD. 20, 21 Because these previous studies have small sample sizes and limited information on other key risk factors, our analysis which benefited from nearly 500 well-characterized patients with CD and carefully adjusted for important confounders significantly extends these previous findings. Moreover, to our knowledge, this is the first study evaluating the interaction between visceral adiposity and genetic predisposition on the risk of CD complications.
Our findings are biologically plausible. Adipocytes secrete TNF-a and express Toll-like receptor suggesting a potential role for adipose tissue in regulating innate immunity. 29 In addition, numerous proinflammatory and anti-inflammatory cytokines including interleukin-6, adiponectin, and resistin have been identified in adipocytes, further suggesting a link between adipocyte tissues and innate immunity. 14, 15, [29] [30] [31] [32] [33] [34] Interestingly, in Immunosuppressive medication includes a history or current use of azathioprine, methotrexate, and 6-mercaptopurine.
comparison with subcutaneous adipose tissue, VAT seems to play a pivotal role in regulating systemic inflammation. 35, 36 Consistent with these observations, compared with total obesity, there seems to be a stronger association between visceral adiposity and risk of metabolic and inflammatory disorders. [37] [38] [39] This is also consistent with our previous and current observations that visceral adiposity as measured by VAT and not total obesity as measured by BMI is likely associated with CD progression. 12 Finally, there are growing data suggesting infiltration of VAT by macrophages and gut microbiota, raising the possibility of local crosstalk between immune function, VAT, and the gut microbiota in the development and progression of CD. 13, 40, 41 Our study has several important strengths that are worth noting. First, our study represents the largest and most comprehensive study evaluating the impact of VAT on CD progression in the context of genetic predisposition. Second, we confirmed all cases of CD and diagnoses of CD complications through the review of medical records, rather than relying on diagnostic codes or self-reported information. Third, in our analyses, we were able to adjust for confounding using detailed information on relevant lifestyle factors, including smoking and BMI. Fourth, we used a previously validated tool to measure VAT volume in all patients minimizing the possibility of measurement errors.
We acknowledge several limitations. First, participants were not systematically screened for the presence of disease complications; and therefore, subclinical complications may have remained undiagnosed in some participants. However, the average disease duration of our participants at the time of enrollment was over 10 years making it unlikely for subclinical disease complications to have gone undiagnosed. Second, because of the crosssectional nature of our study, we were unable to account for changes in the VAT volume overtime. In addition, we acknowledge that VAT volume may also be affected by CD medications including steroids and anti-TNF therapy; and therefore, our observed association could represent a proxy effect. However, we showed that among individuals with multiple CT scans, there was no statistically significant difference between VAT volume before and after disease complications. In addition, in our sensitivity analysis, limiting our study population to individuals with VAT volume measured before the development of complications, yielded similar results. Finally, in our exploratory analyses, we did not observe an effect modification by disease duration on the association between VAT and CD complications. In addition, we adjusted for anti-TNF therapy and ever use of steroids in our MV analyses minimizing the possibility that our observed association may be explained by the use of CD medications. Third, although this is the first study evaluating the interaction between visceral adiposity and genetic predisposition, we acknowledge that robust analysis of gene-environment interaction requires a far greater number of participants. Fourth, we acknowledge that our study is observational; and therefore, we cannot exclude the possibility of residual confounding particularly by factors such as family history of CD and nonsteroidal antiinflammatory drugs that were not available in our cohort. Last, our study is based on an experience of a single tertiary referral center with a predominantly white population; therefore, it is possible that our findings may not be applicable to other populations. However, the average age of diagnosis, rates of complications, and the distribution of lifestyle factors such as smoking and BMI in our study population are similar to other large U.S. population cohorts. 1, 42 In conclusion, we show that visceral adiposity measured by VAT volume is associated with an increased risk of surgery and penetrating disease but not stricturing or perianal disease among patients with CD. Taken together with previous findings that BMI is not associated with the risk of CD complications, our data suggest that visceral rather than total adiposity may negatively influence the long-term risk of progression of CD, regardless of genetic predisposition.
